Eli Lilly and Company $LLY is GKV Capital Management Co. Inc.'s 2nd Largest Position

Key Points

• GKV Capital Management Co. Inc. has reduced its stake in Eli Lilly and Company by 3.3%, making it the firm's second-largest position with holdings valued at approximately $12.35 million.
• Eli Lilly's latest earnings report showed a profit of $6.31 per share, surpassing analysts' estimates, with revenues reaching $15.56 billion—a 37.6% increase year-over-year.
• The company recently announced a quarterly dividend of $1.50, reflecting an annualized dividend yield of 0.8% and a payout ratio of 39.22%.

GKV Capital Management Co. Inc. decreased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 3.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,954 shares of the company's stock after selling 508 shares during the quarter. Eli Lilly and Company comprises about 4.0% of GKV Capital Management Co. Inc.'s portfolio, making the stock its 2nd biggest position. GKV Capital Management Co. Inc.'s holdings in Eli Lilly and Company were worth $12,351,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in LLY. WestEnd Advisors LLC boosted its position in shares of Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the 1st quarter worth $27,000. Citizens National Bank Trust Department boosted its position in shares of Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in shares of Eli Lilly and Company in the 1st quarter worth $40,000. Finally, Mascagni Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company in the 4th quarter worth $43,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson bought 200 shares of the firm's stock in a transaction dated Friday, August 8th. The shares were purchased at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the transaction, the director directly owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director J Erik Fyrwald bought 1,565 shares of the firm's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 4,514 shares of company stock worth $2,894,841 over the last quarter. Company insiders own 0.13% of the company's stock.

Analysts Set New Price Targets

A number of analysts have commented on the company. Wall Street Zen raised Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Erste Group Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Daiwa Capital Markets cut Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target for the company. in a research report on Sunday, August 17th. Morgan Stanley reaffirmed an "overweight" rating and set a $1,135.00 price target (up previously from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Finally, Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $950.17.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded up $0.45 during trading on Friday, reaching $732.41. 2,548,350 shares of the company traded hands, compared to its average volume of 6,895,566. The firm's fifty day simple moving average is $748.68 and its 200 day simple moving average is $786.10. The stock has a market cap of $693.20 billion, a P/E ratio of 47.87, a PEG ratio of 1.02 and a beta of 0.44. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $969.65. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company's revenue was up 37.6% on a year-over-year basis. During the same quarter last year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's payout ratio is currently 39.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.